Azathioprine in the treatment of systemic lupus erythematosus. A controlled study.
D000293:Adolescent; D000328:Adult; D000974:Antibodies, Antinuclear / Q000032:analysis; D001379:Azathioprine / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D001806:Blood Urea Nitrogen; D003404:Creatinine / Q000652:urine; D005260:Female; D005500:Follow-Up Studies; D006760:Hospitalization; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D009504:Neutrophils; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications; D011507:Proteinuria / Q000150:complications; D013997:Time Factors
D000974:Antibodies, Antinuclear; D003404:Creatinine; D001379:Azathioprine; D011241:Prednisone